LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Lakefront Biotherapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$29.79−0.11 (-0.37%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
97.3%
Operating margin
26.5%+63.9 pts over 5 years
Net margin
28.9%+92.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +303.5% | +66.4% | +18.4% | +39.6% | |
| Gross profit | +349.6% | +67.8% | – | – | |
| Net income | +333.1% | – | – | – | |
| EPS, diluted | +334.8% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | 7.1% | -5.2% | 8.5% | |
| Current ratio | 9.70 | 8.45 | 20.15 | |
| Interest coverage | -244.5× | -19.0× | 285.3× | |
| Inventory turnover | – | – | 0.8× | |
| Capex to revenue | 3.4% | 8.9% | 1.2% | |
| Diluted shares | 47M | 65M | 66M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lakefront Biotherapeutics generated €1.99B from operations and spent €130.72M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€1.99B
Used
€130.72M
Capital expenditure€130.72M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero€320.88M
- Cash generatingOperating cash flow above zero-€257.46M
- Return on assets improvedROA up on the prior year1.7% → 7.8%
- Earnings backed by cashOperating cash flow above net income-€257.46M vs €320.88M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.97 → 20.15
- No dilutionShare count did not rise66M → 66M
- Gross margin improvedGross margin up on the prior year87.35% → 97.33%
- More efficientAsset turnover rose0.06 → 0.27